China Stock Alerts
AnPac Bio-Medical Science Co., Ltd.
NASDAQ:
ANPC
Anpac Bio is a biotechnology company focusing on early cancer screening, detection, and marketing a suite of cancer detection tests, including CDA (Cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented Cancer Differentiation Analysis (CDA) technology and proprietary cancer-detection device.
Key Facts
Auditor
Public Listing
Domicile
HQ/Management
Location of Key Operations
IR Contact
Ernst & Young LLP
IPO (January 10, 2020)
British Virgin Islands
Lishui, Zhejiang, China
Tina Xiao, Ascent Investor Relations LLC
917-609-0333
Analyst Coverage
Latest News
September 7, 2021: AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60% | AnPac Bio
September 1, 2021: AnPac Bio’s USA Laboratory Receives Accreditation from the College of American Pathologists | AnPac Bio
June 18, 2021: AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds | AnPac Bio
May 3, 2021: AnPac Bio Reports Fiscal Year 2020 Annual Financial Results (globenewswire.com)
April 30, 2021: AnPac Bio Reports Fiscal Year 2020 Annual Financial Results (89.1% Increase in Revenue and 20.7% Decrease in Net Loss) | AnPac Bio
April 16, 2021: AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020
March 9, 2021: AnPac Bio Developed and Completed Evaluations of New Generation Cancer Detection Sensor with Improved Performance
March 5, 2021: AnPac Bio Regains Compliance with Nasdaq Continued Listing Requirement
February 8, 2021: China’s NMPA Approved Starting of Registration Testing of AnPac Bio Class III Medical Device (For Lung Cancer Auxiliary Diagnosis Utility)
February 1, 2021: AnPac Bio Granted a New US patent on Novel Medical Device for Multi-Cancer Detection